Major Depressive Disorder | Treatment Algorithms: Claims Data Analysis | US | 2022
Major depressive disorder (MDD) is a highly drug-treated condition that utilizes an array of drug classes, including selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), and—as adjunctive therapies—atypical antipsychotics. Although this drug market is well ingrained with generic therapies, MDD patients’ heterogeneous response to current drugs and the need for additional efficacious therapies provide branded agents (e.g., Trintellix [Lundbeck / Takeda], Rexulti [Otsuka / Lundbeck], Spravato [Janssen]) the opportunity to be incorporated into the treatment algorithm. Given MDD’s highly competitive landscape with the presence of both long-established and newer-to-market drugs, drug marketers and developers must understand physicians’ prescribing behaviors in this indication.
QUESTIONS ANSWERED
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed MDD patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed MDD patients?
- How have Trintellix, Rexulti, and Spravato been integrated into the treatment algorithm, and what is their source of business?
- What percentage of MDD patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of MDD patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Key companies: AbbVie, Janssen, Lundbeck, Otsuka Pharmaceutical, Takeda Pharmaceutical
Key drugs: Trintellix, Rexulti, Latuda, Vraylar, Aplenzin, Viibryd, Spravato, citalopram, escitalopram, fluoxetine, sertraline, duloxetine, venlafaxine, aripiprazole, quetiapine, bupropion hydrochloride SR / XL, mirtazapine, etc.
Key analysis provided
Brand / therapy usage across longitudinal patient sample
Newly diagnosed patient analysis
Treatment initiation and progression
Line of therapy analysis
Combination therapy analysis
Source of business for recently treated patients
Persistency and compliance analysis
Product-level patient flowcharts
